PL4143182T3 - Nowe związki użyteczne jako inhibitory polimerazy poli(adprybozy) (parp) - Google Patents
Nowe związki użyteczne jako inhibitory polimerazy poli(adprybozy) (parp)Info
- Publication number
- PL4143182T3 PL4143182T3 PL21724373.2T PL21724373T PL4143182T3 PL 4143182 T3 PL4143182 T3 PL 4143182T3 PL 21724373 T PL21724373 T PL 21724373T PL 4143182 T3 PL4143182 T3 PL 4143182T3
- Authority
- PL
- Poland
- Prior art keywords
- parp
- adp
- ribose
- polymerase
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041018149 | 2020-04-28 | ||
| IN202041047713 | 2020-11-02 | ||
| PCT/IB2021/053382 WO2021220120A1 (en) | 2020-04-28 | 2021-04-23 | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4143182T3 true PL4143182T3 (pl) | 2025-03-31 |
Family
ID=75870674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21724373.2T PL4143182T3 (pl) | 2020-04-28 | 2021-04-23 | Nowe związki użyteczne jako inhibitory polimerazy poli(adprybozy) (parp) |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230234938A1 (pl) |
| EP (1) | EP4143182B1 (pl) |
| JP (1) | JP2023524212A (pl) |
| KR (1) | KR20230002487A (pl) |
| CN (1) | CN115485271B (pl) |
| AU (1) | AU2021262569A1 (pl) |
| BR (1) | BR112022021521A2 (pl) |
| CA (1) | CA3176206A1 (pl) |
| CL (1) | CL2022002966A1 (pl) |
| CO (1) | CO2022016819A2 (pl) |
| DK (1) | DK4143182T3 (pl) |
| ES (1) | ES3014370T3 (pl) |
| FI (1) | FI4143182T3 (pl) |
| IL (1) | IL297537B1 (pl) |
| MX (1) | MX2022013378A (pl) |
| PH (1) | PH12022552854A1 (pl) |
| PL (1) | PL4143182T3 (pl) |
| PT (1) | PT4143182T (pl) |
| SA (1) | SA522441042B1 (pl) |
| WO (1) | WO2021220120A1 (pl) |
| ZA (1) | ZA202211837B (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022090938A1 (en) * | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| MX2023011793A (es) * | 2021-04-08 | 2023-10-12 | Rhizen Pharmaceuticals Ag | Inhibidores de poli(adenosin difosfato-ribosa) polimerasa. |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS50031B (sr) | 1999-01-11 | 2008-11-28 | Agouron Pharmaceuticals Inc., | Triciklični inhibitori poli(adp-riboza)polimeraza |
| ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
| HU228960B1 (hu) | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
| US6664269B2 (en) | 2001-05-08 | 2003-12-16 | Maybridge Plc | Isoquinolinone derivatives |
| AU2003229953A1 (en) | 2002-04-30 | 2003-11-17 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US20040034078A1 (en) | 2002-06-14 | 2004-02-19 | Agouron Pharmaceuticals, Inc. | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase |
| EP1633724B1 (en) | 2003-03-12 | 2011-05-04 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| WO2004087713A1 (en) | 2003-03-31 | 2004-10-14 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| PL1660095T3 (pl) | 2003-07-25 | 2010-07-30 | Cancer Research Tech Ltd | Tricykliczne inhibitory PARP |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| ES2371469T3 (es) | 2003-12-01 | 2012-01-03 | Kudos Pharmaceuticals Limited | Inhibidores de reparación de daños en adn para el tratamiento del cáncer. |
| JP2008510783A (ja) | 2004-08-26 | 2008-04-10 | クドス ファーマシューティカルズ リミテッド | ４−ヘテロアリールメチル置換フタラジノン誘導体 |
| KR100876520B1 (ko) | 2004-09-22 | 2008-12-31 | 화이자 인코포레이티드 | 폴리(ａｄｐ-리보오스) 폴리머라제 억제제의 제조 방법 |
| KR100853601B1 (ko) | 2004-09-22 | 2008-08-22 | 화이자 인코포레이티드 | 8-플루오로-2-｛4-[(메틸아미노)메틸]페닐｝-1,3,4,5-테트라하이드로-6Ｈ-아제피노[5,4,3-ｃｄ]인돌-6-온의포스페이트 염의 다형성 및 무정형 형태 |
| RU2361592C2 (ru) | 2004-09-22 | 2009-07-20 | Пфайзер Инк. | Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы |
| GB0428111D0 (en) | 2004-12-22 | 2005-01-26 | Kudos Pharm Ltd | Pthalazinone derivatives |
| GB0521373D0 (en) * | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| EP2041087A1 (en) | 2006-06-15 | 2009-04-01 | Kudos Pharmaceuticals Limited | 2 -oxybenzamide derivatives as parp inhibitors |
| WO2007144652A2 (en) | 2006-06-15 | 2007-12-21 | Kudos Pharmaceuticals Limited | Parp inhibitors |
| JP2009539962A (ja) | 2006-06-15 | 2009-11-19 | クドス ファーマシューティカルズ リミテッド | Ｐａｒｐ阻害剤としての２−オキシヘテロアリールアミド誘導体 |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| WO2008114114A2 (en) | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
| US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| WO2009050469A1 (en) | 2007-10-17 | 2009-04-23 | Kudos Pharmaceuticals Limited | 4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbonyl) -4 -fluoro-benzyl] -2h-phthalaz in-1-one |
| JP5745283B2 (ja) | 2010-02-12 | 2015-07-08 | ファイザー・インク | ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６Ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンの塩および多形体 |
| US9505749B2 (en) * | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| US20180163271A1 (en) | 2014-01-16 | 2018-06-14 | Clovis Oncology, Inc. | Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity |
| MX387318B (es) * | 2014-04-14 | 2025-03-18 | Arvinas Operations Inc | Moduladores de la proteólisis basados en imida y métodos de uso asociados. |
| RU2705156C2 (ru) | 2014-08-22 | 2019-11-05 | Кловис Онколоджи, Инк. | Таблетки, содержащие большую дозу рукапариба |
| WO2016165650A1 (zh) | 2015-04-17 | 2016-10-20 | 苏州晶云药物科技有限公司 | 奥拉帕尼与尿素的共晶及其制备方法 |
| US20170204067A1 (en) | 2016-01-14 | 2017-07-20 | Scinopharm Taiwan, Ltd. | Crystalline forms of olaparib and manufacturing processes therefor |
| CZ201682A3 (cs) | 2016-02-15 | 2017-08-23 | Zentiva, K.S. | Solvatované krystalické formy olaparibu, jejich příprava a použití |
| WO2017153958A1 (en) | 2016-03-11 | 2017-09-14 | Lupin Limited | Novel polymorphic forms and amorphous form of olaparib |
| WO2017191562A1 (en) | 2016-05-04 | 2017-11-09 | Alembic Pharmaceuticals Limited | Process for the preparation of olaparib and polymorphs thereof |
| CN109563080B (zh) | 2016-08-24 | 2021-07-30 | 台湾神隆股份有限公司 | 奥拉帕尼的制备方法 |
| CN108201536A (zh) | 2016-12-16 | 2018-06-26 | 中国科学院上海药物研究所 | 一种奥拉帕尼口服缓控释药物组合物及其用途 |
| WO2018197463A1 (en) | 2017-04-28 | 2018-11-01 | Akribes Biomedical Gmbh | Rucaparib, talazoparib, veliparib, olaparib and azd 2461 for treating impaired skin wound healing |
-
2021
- 2021-04-23 DK DK21724373.2T patent/DK4143182T3/da active
- 2021-04-23 AU AU2021262569A patent/AU2021262569A1/en active Pending
- 2021-04-23 FI FIEP21724373.2T patent/FI4143182T3/fi active
- 2021-04-23 PL PL21724373.2T patent/PL4143182T3/pl unknown
- 2021-04-23 BR BR112022021521A patent/BR112022021521A2/pt unknown
- 2021-04-23 JP JP2022564815A patent/JP2023524212A/ja active Pending
- 2021-04-23 CN CN202180030479.1A patent/CN115485271B/zh active Active
- 2021-04-23 PH PH1/2022/552854A patent/PH12022552854A1/en unknown
- 2021-04-23 EP EP21724373.2A patent/EP4143182B1/en active Active
- 2021-04-23 US US17/996,030 patent/US20230234938A1/en active Pending
- 2021-04-23 PT PT217243732T patent/PT4143182T/pt unknown
- 2021-04-23 WO PCT/IB2021/053382 patent/WO2021220120A1/en not_active Ceased
- 2021-04-23 KR KR1020227037119A patent/KR20230002487A/ko active Pending
- 2021-04-23 CA CA3176206A patent/CA3176206A1/en active Pending
- 2021-04-23 MX MX2022013378A patent/MX2022013378A/es unknown
- 2021-04-23 ES ES21724373T patent/ES3014370T3/es active Active
-
2022
- 2022-10-23 IL IL297537A patent/IL297537B1/en unknown
- 2022-10-25 SA SA522441042A patent/SA522441042B1/ar unknown
- 2022-10-26 CL CL2022002966A patent/CL2022002966A1/es unknown
- 2022-10-31 ZA ZA2022/11837A patent/ZA202211837B/en unknown
- 2022-11-23 CO CONC2022/0016819A patent/CO2022016819A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021220120A1 (en) | 2021-11-04 |
| MX2022013378A (es) | 2023-02-15 |
| IL297537B1 (en) | 2025-12-01 |
| FI4143182T3 (fi) | 2025-03-04 |
| ES3014370T3 (en) | 2025-04-22 |
| EP4143182A1 (en) | 2023-03-08 |
| TW202140451A (zh) | 2021-11-01 |
| JP2023524212A (ja) | 2023-06-09 |
| US20230234938A1 (en) | 2023-07-27 |
| CA3176206A1 (en) | 2021-11-04 |
| CN115485271A (zh) | 2022-12-16 |
| ZA202211837B (en) | 2024-02-28 |
| PH12022552854A1 (en) | 2023-03-27 |
| SA522441042B1 (ar) | 2024-01-27 |
| CL2022002966A1 (es) | 2023-04-21 |
| KR20230002487A (ko) | 2023-01-05 |
| CN115485271B (zh) | 2025-07-15 |
| BR112022021521A2 (pt) | 2023-01-24 |
| PT4143182T (pt) | 2025-03-13 |
| EP4143182B1 (en) | 2024-12-11 |
| AU2021262569A1 (en) | 2022-11-24 |
| CO2022016819A2 (es) | 2023-02-16 |
| IL297537A (en) | 2022-12-01 |
| DK4143182T3 (da) | 2025-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170982T1 (hr) | Dihidropiridoftalazinonski inhibitori poli(adp-ribozne)polimeraze (parp) | |
| HUS1800022I1 (hu) | Amid-szubsztituált indazol-származékok mint poli(ADP-ribóz)-polimeráz (PARP) inhibitorok | |
| WO2010111626A3 (en) | Poly (adp-ribose) polymerase (parp) inhibitors | |
| IL307343A (en) | Pyridinyl substituted oxisoisoindoline compounds | |
| IL297537B1 (en) | New compounds useful as poly(adp-ribose) polymerase (parp) inhibitors | |
| PL3749646T3 (pl) | Związki heteroarylowe jako inhibitor kinazy | |
| PT3956322T (pt) | Inibidor seletivo de cinase jak1 | |
| GB202008201D0 (en) | Inhibitor compounds | |
| ZA202303688B (en) | Substituted tricyclic compounds | |
| GB202004960D0 (en) | Inhibitor compounds | |
| IL318955A (en) | Modified pyridinone compounds as CBL-B inhibitors | |
| TWI907416B (zh) | 可用作聚(ａｄｐ-核糖)聚合酶(ｐａｒｐ)抑制劑之新型化合物 | |
| GB202103569D0 (en) | No title | |
| GB202110373D0 (en) | Inhibitor compounds | |
| IL307339A (en) | Poly(ADP-ribose) polymerase inhibitors | |
| GB202112240D0 (en) | Inhibitor compounds | |
| GB202107325D0 (en) | Inhibitor compounds | |
| HK40106493A (en) | Inhibitors of poly(adp-ribose) polymerase | |
| GB202016964D0 (en) | Inhibitor compounds | |
| GB202012969D0 (en) | Inhibitor compounds | |
| GB202008205D0 (en) | Inhibitor compounds | |
| GB202020368D0 (en) | No title | |
| GB202015850D0 (en) | No title | |
| HK40069065A (zh) | Jak1选择性激酶抑制剂 | |
| GB202007805D0 (en) | No title |